Characterization of gentamicin-susceptible strains of methicillin-resistant Staphylococcus aureus involved in nosocomial spread. 1998

N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
Laboratoire de Bactériologie-Hygiène, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. sougakof@lmcp.jusssieu.fr

We report an outbreak of epidemic Staphylococcus aureus strains characterized by an unusual heterogeneous resistance to methicillin and resistance to tobramycin but susceptibility to gentamicin (gentamicin-susceptible methicillin-resistant S. aureus [GS-MRSA]), contrasting with gentamicin-resistant homogeneous MRSA (GR-MRSA) that have been endemic in our hospital since the 1970s. A total of 97 GS-MRSA strains, which were shown by DNA hybridization to carry the mecA and ant(4')-Ia genes, were studied. The 40 GS-MRSA strains isolated at the beginning of the outbreak (January 1992 to June 1993) were typed by using resistance patterns, phage typing, serotyping, and pulsed-field gel electrophoresis and were compared with GR-MRSA and methicillin-susceptible S. aureus (MSSA) strains isolated during the same period. Two dominant clones, A::1 and B::3, and one minor clone, C::5, were identified among the 40 GS-MRSA strains, according to pulsotypes (A to C) and their resistance patterns (1, 3, and 5), which were distinguishable from those of GR-MRSA and MSSA strains. A selection of 57 GS-MRSA strains, isolated from 1994 to 1996, were clustered in the same three clones. However, their distribution had changed in comparison with that in the 1992 to 1993 period: clone A::1 remained dominant (47 versus 42.5%), whereas clone B::3 progressively declined (5 versus 35%) and clone C::5, the most susceptible to antibiotics, spread (44 versus 2.5%). Epidemiological investigations revealed that some clones had been introduced via patients transferred from other hospitals and that cross-infection occurred within and between wards. Major changes in the use of antibiotics, especially aminoglycosides, cyclines, and macrolides, likely played a role in the emergence and spread of GS-MRSA strains.

UI MeSH Term Description Entries
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D003428 Cross Infection Any infection which a patient contracts in a health-care institution. Hospital Infections,Nosocomial Infections,Health Care Associated Infection,Health Care Associated Infections,Healthcare Associated Infections,Infection, Cross,Infections, Hospital,Infections, Nosocomial,Cross Infections,Healthcare Associated Infection,Hospital Infection,Infection, Healthcare Associated,Infection, Hospital,Infection, Nosocomial,Infections, Cross,Infections, Healthcare Associated,Nosocomial Infection
D004196 Disease Outbreaks Sudden increase in the incidence of a disease. The concept includes EPIDEMICS and PANDEMICS. Outbreaks,Infectious Disease Outbreaks,Disease Outbreak,Disease Outbreak, Infectious,Disease Outbreaks, Infectious,Infectious Disease Outbreak,Outbreak, Disease,Outbreak, Infectious Disease,Outbreaks, Disease,Outbreaks, Infectious Disease
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D005839 Gentamicins A complex of closely related aminoglycosides obtained from MICROMONOSPORA purpurea and related species. They are broad-spectrum antibiotics, but may cause ear and kidney damage. They act to inhibit PROTEIN BIOSYNTHESIS. Gentamicin Sulfate (USP),Gentamycin,G-Myticin,Garamycin,Gentacycol,Gentamicin,Gentamicin Sulfate,Gentamycins,Gentavet,Genticin,G Myticin,GMyticin,Sulfate, Gentamicin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000900 Anti-Bacterial Agents Substances that inhibit the growth or reproduction of BACTERIA. Anti-Bacterial Agent,Anti-Bacterial Compound,Anti-Mycobacterial Agent,Antibacterial Agent,Antibiotics,Antimycobacterial Agent,Bacteriocidal Agent,Bacteriocide,Anti-Bacterial Compounds,Anti-Mycobacterial Agents,Antibacterial Agents,Antibiotic,Antimycobacterial Agents,Bacteriocidal Agents,Bacteriocides,Agent, Anti-Bacterial,Agent, Anti-Mycobacterial,Agent, Antibacterial,Agent, Antimycobacterial,Agent, Bacteriocidal,Agents, Anti-Bacterial,Agents, Anti-Mycobacterial,Agents, Antibacterial,Agents, Antimycobacterial,Agents, Bacteriocidal,Anti Bacterial Agent,Anti Bacterial Agents,Anti Bacterial Compound,Anti Bacterial Compounds,Anti Mycobacterial Agent,Anti Mycobacterial Agents,Compound, Anti-Bacterial,Compounds, Anti-Bacterial
D013211 Staphylococcus aureus Potentially pathogenic bacteria found in nasal membranes, skin, hair follicles, and perineum of warm-blooded animals. They may cause a wide range of infections and intoxications.
D016106 Methicillin Resistance Non-susceptibility of a microbe to the action of METHICILLIN, a semi-synthetic penicillin derivative. Methicillin-Resistant,Methicillin Resistant,Resistance, Methicillin

Related Publications

N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
January 1980, Infection control : IC,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
January 2003, Microbial drug resistance (Larchmont, N.Y.),
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
May 1996, The American journal of medicine,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
September 2002, International journal of antimicrobial agents,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
January 1996, Chemotherapy,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
August 2009, Antimicrobial agents and chemotherapy,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
August 2006, Infection control and hospital epidemiology,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
November 1982, Antimicrobial agents and chemotherapy,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
October 2007, Journal of clinical microbiology,
N Lemaître, and W Sougakoff, and A Masmoudi, and M H Fievet, and R Bismuth, and V Jarlier
June 2001, Journal of clinical microbiology,
Copied contents to your clipboard!